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ABSTRACT
Background: Few studies have examined the efficacy or safety of a transdermal β2 agonist as add-on medi-
cation to long-term leukotriene receptor antagonist (LTRA) therapy in pediatric asthma patients.
Methods: In this randomized, open-label, multicenter clinical trial, children aged 4-12 years on long-term
LTRA therapy were treated with tulobuterol patches (1-2 mg daily) or oral sustained-release theophylline (usual
dose, 4-5 mgkg daily) for 4 weeks. LTRAs were continued throughout the trial. Outcomes included volume of
peak expiratory flow (% PEF), fractional exhaled nitric oxide (FeNO), clinical symptoms and adverse events.
Results: Thirty-three and 31 patients were treated with tulobuterol patches and theophylline, respectively.
% PEF measured in the morning and before bedtime was significantly higher at all times in the treatment period
compared with baseline in the tulobuterol patch group (p < 0.001), and was significantly higher in the tu-
lobuterol patch group compared with the theophylline group. FeNO was similar and unchanged from baseline in
both groups. There were no drug-related adverse events in either group.
Conclusions: These results suggest that short-term use of a transdermal β2 agonist is an effective therapy for
pediatric asthma without inducing airway inflammation in children on long-term LTRA therapy.
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INTRODUCTION
Low-dose inhaled corticosteroids (ICS) or leukot-
riene receptor antagonists (LTRAs) are widely used
for long-term management of pediatric asthma.1 ICS
are generally recommended as the initial controller
medication, although LTRAs are increasingly being
considered instead of ICS.2-4 Indeed, LTRAs are par-
ticularly useful in patients who need to avoid steroids,
and in patients with allergic rhinitis.5-7 They may also
be useful in infants, as they can provide effective
long-term asthma control, similar to that achieved
with low-dose ICS.8 The most common add-on medi-
cations in mild pediatric asthma are β2 stimulants, al-
though the Japanese Pediatric Guidelines for the
Treatment and Management of Bronchial Asthma
also recommend theophylline as an add-on medica-
tion for mild asthma.9
The tulobuterol patch (Abbott Japan Co., Ltd., To-
kyo, Japan) is a transdermal β2-adrenergic agonist
that was approved in Japan in 1998, and is widely ac-
cepted by patients for management of asthma or
wheezing. The tulobuterol patch has a favorable phar-
macokinetic profile,10 and is associated with good ad-
herence11 for the management of asthma or wheez-
ing. The tulobuterol patch provides a prolonged bron-
chodilator effect because it contains molecular and
crystallized forms of tulobuterol. Upon application to
the skin, the molecular tulobuterol is gradually ab-
sorbed percutaneously. The depleted tulobuterol
molecules in the patch are then replenished by disso-
ciation of crystallized tulobuterol into absorbable tu-
lobuterol molecules. Therefore, although tulobuterol
is a short-acting β2 agonist, each patch provides ef-
fects lasting over 24 hours in adults10 and chil-
dren,12,13 thus providing long-acting β2 agonist activ-
ity.
To date, however, no studies have investigated the
efficacy of the tulobuterol patch as an add-on medica-
tion to LTRA for the management of mild pediatric
asthma. The Japanese Pediatric Guidelines recom-
mend that studies should include theophylline as the
first-line add-on medication. Therefore, the aim of
this study was to compare the effects of short-term
continuous use of the tulobuterol patch with that of
sustained-release theophylline as add-on medications
for children aged 4-12 years with mild-to-moderate
asthma on long-term treatment with a LTRA.
METHODS
PATIENTS
Children aged 4-12 years with bronchial asthma un-
der treatment for mild persistent asthma diagnosed
according to the Japanese pediatric guidelines for the
treatment and management of bronchial asthma,9 or
continued wheezing, dyspnea or diurnal variation in
peak expiratory flow (PEF) 20% despite treatment
with LTRAs, or stable PEF, were eligible for this
study. Children meeting any of the following criteria
were excluded: treatment with a long-acting β2 ago-
nist or regular treatment with an oral β2 agonist; his-
tory of hypersensitivity to the tulobuterol patch or
skin diseases such as atopic dermatitis, for whom the
tulobuterol patch was considered inappropriate; dis-
eases considered unsuitable for treatment with β2 ag-
onists (e.g., hyperthyroidism, hypertension, heart dis-
ease or diabetes mellitus) or theophylline (e.g., epi-
lepsy, hyperthyroidism, acute nephritis, congestive
heart failure, liver disease); history of serious adverse
reactions to tulobuterol or theophylline; history of se-
vere neurological disorders (e.g., epilepsy, convul-
sions or abnormal electroencephalogram); or fever
37.5℃. Patients who were deemed inappropriate to
participate in the study by their attending physician
were also excluded from the study.
Diurnal variation in PEF was calculated as [(daily
maximum PEF) - (daily minimum PEF)] {[(daily
maximum PEF) + (daily minimum PEF)]2} × 100.
Reliable PEF was defined as the difference be-
tween the second highest and the highest PEF value
being <15% of the highest PEF measurement of three
consecutively measured values.
The nature of the study was explained to all pa-
tients and their parentsguardian, and written in-
formed consent was obtained from the parents
guardians. Informed consent was also obtained from
older children when considered appropriate. The
study was carried out in accordance with the princi-
ples of the Declaration of Helsinki, 1995, and revised
in Seoul, 2008. The clinical trial registration number
is UMIN 000002921.
Patients were withdrawn from the study in the
event of any of the following: a child or parentguard-
ian requesting discontinuation of the study medica-
tion; continuation of the study being deemed difficult
because of adverse reactions, worsening of complica-
tions (including where ICS were considered neces-
sary) or worsening of symptoms; the child not attend-
ing the follow-up visits; or any other situation in
which continuing the study was deemed inappropri-
ate by the attending physician.
STUDY DESIGN AND TREATMENTS
This was a randomized, open-label, parallel-group,
multicenter (15 centers) clinical study performed in
Japan between January 2007 and June 2009. Japanese
children meeting the eligibility criteria entered a 1-2-
week run-in phase and were treated with a LTRA
(pranlukast or montelukast) alone. LTRAs were used
in accordance with their approved dose regimens. At
the end of the run-in phase, patients received either
the tulobuterol patch (Abbott Japan Co., Ltd.) or
sustained-release theophylline (AstraZeneca, London,
UK) for 4 weeks.
Randomization was performed using the sealed en-
velope method using a randomization table generated
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by Kumiko Ohta at the Clinical Research Division of
National Mie Hospital.
The tulobuterol patch was applied once-daily at
bedtime to the chest, back or upper arm, at a dose of
1 mg for children aged 3-<9 years, or 2 mg for chil-
dren aged 9 years. Sustained-release theophylline
(4-5 mgkg per dose; twice-daily in the morning and
at bedtime) was administered in accordance with the
Japanese Pediatric Guidelines for the Treatment and
Management of Bronchial Asthma.9 Inhaled or oral
steroids were prohibited from 1 month before study
commencement. Other β2 agonists were prohibited,
except for the use of oralinhaled β2 agonists at the
onset of an asthma exacerbation. Anti-allergic drugs,
inhaled anticholinergic, antihistamine, antitussives
expectorants and traditional Chinese medicines initi-
ated before the study were allowed, providing their
dose and regimen remained unchanged throughout
the study. Patients requiring ICS therapy during the
treatment period to treat deteriorating symptoms
were excluded from the evaluation.
ENDPOINTS
The primary endpoint was the volume of peak expira-
tory flow (% PEF) measured in the morning and be-
fore bedtime. Secondary endpoints included asthma
symptoms, airway inflammation levels, use of as-
needed β2 agonists, and adverse drug reactions. Pa-
tients were asked to perform PEF tests three times in
the morning and before bedtime every day, and the
maximum value at each time was recorded in a diary.
The diary was also used to record clinical symptoms,
including symptoms of exacerbations, frequency of
exacerbations, coughing, sputum, activities of daily
living, nocturnal sleep, and frequency of using as-
needed β2 agonists. Airway inflammation was as-
sessed by measuring fractional exhaled nitric oxide
(FeNO) using a NIOX MINO (Aerocrine, Solna, Swe-
den) during the run-in period, and after 2 and 4
weeks of treatment. Symptoms and laboratory
anomalies that newly occurred or deteriorated during
the study were recorded. For all events, the date of
onset and resolution, severity, treatment required,
outcome and causal relationship with the study drug
were recorded.
STATISTICAL ANALYSIS
Considering the results of prior studies in pediatric
patients14,15 the change in PEF from baseline was as-
sumed to be 5.0 Lmin in patients receiving theophyl-
line and 18.0 Lmin in those receiving treatment with
the tulobuterol patch, with a common standard devia-
tion of 26.0 Lmin. Therefore, with a two-sided signifi-
cance level of 5% and 80% power, the sample size was
calculated to be 64 patients per group. Allowing for a
10% dropout rate, the target sample size was 70 pa-
tients per group. The secondary endpoint of asthma
symptoms was assessed on a 4-point scale that has
been used for many years in clinical practice in Ja-
pan.16 A score of 1 was given to patients with a cough.
A score of 3 was given to patients with a cough, mild
wheezing, no retractive breathing, or mild retractive
breathing. A score of 6 was given to patients who had
a cough, apparent wheezing, apparent retractive
breathing, and dyspnea. A score of 9 was given to pa-
tients who had a cough, marked wheezing, markedly
retractive breathing, and marked dyspnea. Scores of
2, 4, 5, 7, and 8 do not exist. The scoring system uses
scores of 1, 3, 6, and 9 instead of 1, 2, 3, and 4 to pro-
vide a weighting for the degree of exacerbation. For
comparisons of demographic data and baseline char-
acteristics between the two groups, χ2 test, Fisher’s
exact probability test, Wilcoxon’s two-sample test and
Student’s two-sample test were used as appropriate.
Student’s one-sample and two-sample tests were used
for within-group and between-group comparisons of
efficacy outcomes. For all analysis, values of P < 0.05
were considered statistically significant. All statistical
analyses were done using SAS ver. 9.1 (SAS Institute,
Cary, NC, USA).
RESULTS
PATIENT CHARACTERISTICS
Overall, 80 patients were screened and considered
eligible for the study. Of these, 14 withdrew consent
before treatment allocation. Thirty-four patients were
treated with tulobuterol patches and 32 patients with
theophylline. Two patients were withdrawn from the
study: one patient allocated to the theophylline group
used a generic tulobuterol patch during the study and
one patient in the tulobuterol patch group had a com-
pliance of 10%. Therefore, 33 patients treated with
tulobuterol patches and 31 with theophylline were
analyzed. The characteristics of patients in both
groups are summarized in Table 1; these characteris-
tics were not significantly different between the two
groups.
% PEF
Figure 1 shows the changes in % PEF from baseline
(run-in period) to week 4 of treatment. % PEF meas-
ured in the morning (Fig. 1A) and before bedtime
(Fig. 1B) improved significantly in the tulobuterol
group within 1 week of starting treatment, and contin-
ued to increase thereafter.
Although % PEF measured in the morning and be-
fore bedtime in the theophylline group also increased
significantly at week 1, the magnitude of the increase
was much smaller than that seen in the tulobuterol
group, and % PEF remained significantly lower than
those in the tulobuterol patch group. Interestingly,
the improvement in % PEF measured before bedtime
at week 1 in the theophylline group was lost by week
2, as % PEF measured before bedtime at weeks 2, 3
and 4 was not significantly different to that at baseline
in this group.
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Table　1　 Patient characteristics
Tulobuterol patch Theophylline p
n 33 31
Sex (M/F) 17/16 21/10 0.212*
Age (years)   7.5 ± 2.0   8.5 ± 2.0 0.056
Height (cm) 124.5 ± 13.0 128.3 ± 13.1 0.250
Weight (kg)  26.7 ± 9.1  27.6 ± 9.4 0.713
Concomitant use of antihistamines (Yes/No) 8/25 9/22 0.779*
% PEF in the morning  84.6 ± 13.7  89.8 ± 13.6 0.055
% PEF before bedtime  90.7 ± 11.4  93.6 ± 12.1 0.248
FeNO (ppb)  35.7 ± 22.2  36.6 ± 23.6 0.881
P-values were determined using t-tests, except *Fischer’s exact test. PEF, peak expiratory fl ow; FeNO, fractional exhaled nitric oxide.
Fig.　1　Changes in % peak expiratory fl ow (PEF) in the morning (A) and before bedtime (B). *P < 0.05, **P < 0.001, and 
***P < 0.001 vs run-in (Student’s one-sample test) or theophylline (Student’s two-sample test).
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Fig.　2　Changes in fractional exhaled nitric oxide (FeNO). 
There were no signifi cant differences in FeNO at weeks 2 or 
4 vs run-in (Student’s one-sample test) or vs theophylline 
(Student’s two-sample test).
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FeNO, a marker of eosinophilic asthma inflammation,
was determined at baseline and at the end of weeks 2
and 4 on treatment. As shown in Figure 2, there were
no marked changes in FeNO during the study in
either group. This indicates that neither the tu-
lobuterol patch nor theophylline affected airway in-
flammation.
ASTHMA EXACERBATION SCORES AND SYMP-
TOMS
Exacerbation scores, which were determined based
on the symptoms and frequency of exacerbations,
were determined during the run-in period, during
weeks 1-2, and weeks 3-4 of treatment. Scores im-
proved in both groups, from 14.2 ± 20.9 in the run-in
period to 8.2 ± 22.2 during weeks 3-4 in the tu-
lobuterol patch (p = 0.41), and from 10.5 ± 14.6 to 7.6
± 15.8 in the theophylline group (p = 0.43), although
these improvements were not statistically significant
(Table 2).
Asthma symptoms in terms of the number of
exercise-induced exacerbations and the number of
days with good sleep were also recorded over 2
weeks in the run-in period and at weeks 3-4. As
shown in Table 2, the number of exercise-induced ex-
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Table　2　Asthma symptoms and frequency of β2 agonist administration
Tulobuterol patch Theophylline
Exacerbation scores During the run-in period 14.2 ± 20.9 10.5 ± 14.6
At weeks 1-2 of treatment 13.3 ± 24.6  7.6 ± 15.7
At weeks 3-4 of treatment  8.2 ± 22.2  7.6 ± 15.8
Number of exercise-induced exacerbations During the run-in period  0.9 ± 2.5  0.4 ± 1.1
At weeks 3-4 of treatment  0.2 ± 0.7  0.1 ± 0.2
Number of days with good sleep (%) During the run-in period 10.2 ± 5.8 10.9 ± 6.6
(72.9) (77.9)
At weeks 3-4 of treatment 13.0 ± 5.0 12.3 ± 4.7
(92.9) (87.9)
Frequency of oral β2 agonist administration 
(n)
During the run-in period  1.7 ± 5.2  0.1 ± 0.4
At weeks 1-2 of treatment  0.5 ± 1.7  0.5 ± 1.2
At weeks 3-4 of treatment  0.1 ± 0.4  1.1 ± 5.6
Frequency of inhaled β2 agonist adminis-
tration (n)
During the run-in period  0.5 ± 1.8 0
At weeks 1-2 of treatment  0.3 ± 0.8  0.1 ± 0.2
At weeks 3-4 of treatment  0.4 ± 1.2  0.5 ± 3.1
acerbations decreased in both groups, while the num-
ber and proportion of days with good sleep increased
in both groups. However, these changes did not
reach statistical significance. The frequency of oral
and inhaled β2 agonist administration tended to de-
crease between the observation period and week 3-4
of treatment in the tulobuterol patch group, but in-
creased in the theophylline group (Table 2).
SAFETY
Adverse events were rare. Acute upper respiratory in-
flammation was reported in one patient treated with
theophylline, but was not considered related to the in-
vestigational drug. No drug-related adverse effects
occurred during the study.
DISCUSSION
In this study, we compared the effects of short-term
continuous use of a transdermal β2 agonist (tu-
lobuterol patch) with those of sustained-release theo-
phylline as add-on medications in combination with a
LTRA in 4-12-year-old children with mild persistent
asthma or moderate pediatric asthma. We found that
the tulobuterol patch significantly increased % PEF in
the morning and before bedtime at all times in the
treatment period compared with baseline values. Al-
though theophylline elicited significant increases in
morning % PEF at weeks 1, 3 and 4, and in % PEF
measured before bedtime at week 1, the magnitude
of the increase at all times (except % PEF measured
before bedtime at week 1) during the treatment pe-
riod was significantly smaller than that achieved with
the tulobuterol patch. The frequency of as-needed β2
agonist administration tended to decline over time in
the tulobuterol patch group, although increased
slightly in the theophylline group. These results indi-
cate that add-on tulobuterol patch is superior to theo-
phylline in terms of improving % PEF in children with
mild-to-moderate asthma on long-term treatment with
a LTRA.
Among adults, patients with moderate to severe
asthma experienced significant improvements in
health-related quality of life and morning % PEF fol-
lowing 4 weeks of treatment with the tulobuterol
patch. Morning % PEF was significantly lower in pa-
tients treated with the tulobuterol patch than in those
treated with salmeterol, although health-related qual-
ity of life scores were similar in both groups.17
Of note, we observed no tachyphylaxis during con-
tinuous use of the tulobuterol patch for 4 weeks.
Tachyphylaxis is a phenomenon characterized by de-
creased responsiveness of a receptor following con-
tinuous exposure to an agonist; in this setting tachy-
phylaxis results in a reduced bronchodilator effect of
the β2 agonist,18 as has already been reported for al-
buterol.19 It is also important to consider that tachy-
phylaxis is particularly common in patients with air-
way inflammation.20 However, in our study, the im-
provements in respiratory function (i.e., % PEF) in the
tulobuterol group seemed to increase gradually, with-
out signs of decreasing over time, although we can-
not rule out the possibility of a plateauing or reduc-
tion in % PEF with longer-term usage. Salmeterol, a
long-acting β2 agonist, was also found to not induce
tachyphylaxis,21 suggesting that the tulobuterol patch
may elicit similar effects to salmeterol.
NO levels are correlated with the eosinophil count
in sputum and methacholine airway hypersensitivity,
a useful marker of airway inflammation in asthma.22 It
has been reported that long-term continuous use of
β2 agonists may enhance airway inflammation.23-25
Therefore, we assessed FeNO as a surrogate marker
for airway inflammation that can be easily assessed in
the clinic. After 4 weeks of treatment, there were no
insignificant increases in FeNO in either group,
which suggests that these drugs in combination with
Katsunuma T et al.
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a LTRA do not worsen airway inflammation in pediat-
ric asthma.
Considering that asthma is at least partly caused by
eosinophilic inflammation and that β2 agonists are
generally suspected of aggravating inflammation, par-
ticularly when used as monotherapy,26,27 the con-
comitant use of a β2 agonist with an anti-inflammatory
drug, such as an ICS, is often preferred.28 However,
in a study in adults, adding the tulobuterol patch to
ICS significantly improved bronchial hyperrespon-
siveness and significantly decreased the sputum
eosinophil count compared with ICS alone.29 The re-
sults of that study and of our own should allay these
fears, as the use of the tulobuterol patch in combina-
tion with a LTRA did not worsen FeNO in our study.
The present results suggest two important avenues
for future research. First, it should be determined if
there is an optimal duration of treatment with tu-
lobuterol patch, if treatment should continue until
complete normalization of airway function is
achieved, or if we should discontinue treatment once
the patient achieves a certain threshold of lung func-
tion (e.g., based on % PEF relative to individuals with-
out pediatric asthma). Clearly, continuing long-acting
β2 agonist therapy in patients with good lung function
and marked improvements in airway inflammation is
unnecessary, as they could benefit more from as-
needed short-acting treatments. Second, it seems
likely that not all patients show clinically significant
improvements in lung functionairway responsive-
ness, despite treatment with either drug. In this situ-
ation, the patient may benefit from switching to or
adding ICS therapy but, the question remains, how
long should we wait until we switchintensify ther-
apy? Studies focusing on these two avenues are now
needed to provide the evidence needed to optimize
the treatment algorithm for pediatric asthma.
The results of this study should be interpreted with
care considering the limitations. First, this was an
open-label study. Although this could have been
avoided by providing the participants with placebo
patches or tablets, we believe that a blinded study
would have led to difficulties in adherence to the as-
signed treatments.
A second limitation is that the sample size was
smaller than planned, which reduced the statistical
power of the study. Because general practices were
included among the institutes participating this study,
the study plan that was followed was different from
the original study plan and patient enrollment took
longer than was foreseen, limiting the number of pa-
tients that could be enrolled within the time-frame of
the study. Nevertheless, the difference in PEF be-
tween the two groups was statistically significant and
the magnitude of the difference was larger than that
originally hypothesized for the sample size calcula-
tion. Of course, additional studies would be useful to
confirm the current findings.
Third, although the mean exacerbation scores
showed large numerical differences between the run-
in period and weeks 3-4 of treatment, the differences
were not statistically significant. This is probably be-
cause of the large variation in values, and because
our study was underpowered to detect significant dif-
ferences in this parameter. This variation may be
driven by outliers, or marked variation in responses
among individual patients. Future studies aimed at
examining improvements in exacerbation scores may
need to include a larger number of patients to provide
adequate power for this analysis.
The final limitation that should be discussed is that
we used % PEF measured in the morning and before
bedtime as the primary endpoint in children ranging
in age from 4 to 12 years. Many clinicians may be-
lieve that % PEF is inaccurate in younger children be-
cause of the difficulty in obtaining reliable and consis-
tent recordings. However, % PEF is often used as a
primary endpoint in studies of pediatric asthma,30,31
and reliable values can be achieved in children aged
4-5 years with appropriate instruction.1 To ensure
that PEF could be measured reliably, only patients
with stable PEF, defined as the difference in three
PEF values within 15%, were included in this study.
In conclusion, we found that the tulobuterol patch
elicited significantly greater improvements in % PEF
measured in the morning and before bedtime com-
pared with sustained-release theophylline in children
on long-term LTRA therapy. These effects of the tu-
lobuterol patch were achieved without worsening
FeNO, indicating that it does not exacerbate airway
inflammation in children. These results suggest that
short-term continuous use of a transdermal β2 agonist
is an effective therapy for pediatric asthma without in-
ducing airway inflammation.
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